Evidence map›Paper›PMID 31619215›Full record

ArticleBMC urology2019

PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study.

A Rodríguez Antolín, L Martínez-Piñeiro, M E Jiménez Romero, J B García Ramos, D López Bellido, J Muñoz Del Toro, A García García-Porrero, F Gómez Veiga

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Patient attitudes and experiences towards exercise during oncological treatment. A qualitative systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

A Rodríguez AntolínUrology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
L Martínez-PiñeiroUrology Department, Hospital Universitario La Paz, Madrid, Spain.
M E Jiménez RomeroUrology Department, Hospital Universitario de Puerto Real, Cádiz, Spain.
J B García RamosUrology Department, Complejo Hospitalario Universitario de Huelva, Huelva, Spain.
D López BellidoUrology Department, Complejo Hospitalario Universitario de Orense, Orense, Spain.
J Muñoz Del ToroJanssen Medical Department, Paseo de las 12 estrellas 5-7, 28042, Madrid, Spain. jmunozde@its.jnj.com.
A García García-PorreroJanssen Medical Department, Paseo de las 12 estrellas 5-7, 28042, Madrid, Spain.
F Gómez VeigaUrology Department, Hospital Clínico Universitario de Salamanca e Instituto de investigación Biomédica de Salamanca (GITUR-IBSAL), Salamanca, Spain.
Madrid Health Service · ESComplejo Hospitalario de Ourense · ESHospital Universitario 12 De Octubre · ESHospital Universitario La Paz · ESHospital Universitario Puerto Real · ESInstituto de Investigación Biomédica de Salamanca · ESUniversidad de Huelva · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice.

methodsThis was a cross-sectional, multicentre study. Male chemo-naïve adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables).

resultsA total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 ± 16.3 and 108.7 ± 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone ≥3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone ≥3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively).

conclusionOur data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naïve CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naïve mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT.

trial registrationNot applicable since it is not an interventional study.

Indexed as

Quality of LifeAgedAged, 80 and overCross-Sectional StudiesFatigueHumansMaleMiddle AgedPrevalenceProstatic Neoplasms, Castration-ResistantBFI questionnaireCastration-resistant prostate cancerFACT-P questionnaireFatigueQuality of life

Identifiers

PMID31619215
PMCPMC6796370
OpenAlexW2980537719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.